Key facts
- Notable investors include Delft Enterprises, Graduate Ventures, Thematic Technology Transfer, Gulliver (Netherlands), Philips — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Lyla Systems
- ·The full record, as it builds
Funding rounds
No funding rounds for Lyla Systems are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Lyla Systems
Developer of a radiopharmaceutical quality assurance device designed to assess the safety and quality of radioactive isotopes. The company's device facilitates the thorough evaluation of targeted radionuclide therapy used in promising new cancer treatments and captures radiation in a sealed cartridge, enabling pharmacists to reduce contamination risks and improve lab safety and treatment outcomes.
- Sector
- Healthcare
- HQ
- Delft, Netherlands
- Founded
- 2023
- Employees
- 5
- Website
- lyla.systems/
- Ownership
- Privately Held (backing)
Lyla Systems doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Lyla Systems shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Lyla Systems in its N-PORT filings yet. We sweep new filings monthly.